Pillstats
Rx only · Tablet · Oral

Irbesartan

Irbesartan

20 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US76 NDCs
20 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)83818
US makers21 labelers
Packages193
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 39 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.034$0.069$0.103$0.138Dec 2025Apr 2026Jul 2026
$0.116
Latest avg · Jul 22, 2026
-3%
Since Dec 17, 2025
20
Active US suppliers
31%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

26K53K79K105K2025 Q12025 Q22025 Q32025 Q42026 Q1
80K
Rx · 2026 Q1
4.3M
Units dispensed
-11%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it20 active · 1 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Alembic Pharmaceuticals Limitedunknown30SUPPLYING
Bryant Ranch Prepackrepackager30SUPPLYING
Camber Pharmaceuticals, Inc.unknown18SUPPLYING
Macleods Pharmaceuticals Limitedunknown15SUPPLYING
Proficient Rx LPunknown13SUPPLYING
Amneal Pharmaceuticals LLCunknown11SUPPLYING
Aurobindo Pharma Limitedunknown10SUPPLYING
Solco Healthcare US, LLCunknown9SUPPLYING
Unichem Pharmaceuticals (USA), Inc.unknown9SUPPLYING
Jubilant Cadista Pharmaceuticals Inc.unknown9SUPPLYING
A-S Medication Solutionsunknown7SUPPLYING
ScieGen Pharmaceuticals, Inc.unknown6SUPPLYING
Chartwell RX, LLCunknown6SUPPLYING
REMEDYREPACK INC.repackager5SUPPLYING
NorthStar RxLLCunknown4SUPPLYING

+ 6 more labelers

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Jan 21, 2025
    RECALLRecall (Class II): Irbesartan Tablets USP, 300 mg, 50 Tablets (5 x 10) Unit Dose per carton, Manufactured for: AvKARE, Pulaski, TN 38478. …

    Out of Specification for Dissolution — Recalling firm: AvKARE — Nationwide in the USA

  • Jul 18, 2022
    RECALLRecall (Class II): Irbesartan Tablets, USP, 75 mg, 90- count bottle, Rx only, Manufactured by: Jubilant Generics Ltd. Roorkee- 247661, Ind…

    Failed Dissolution Specifications — Recalling firm: Jubilant Cadista Pharmaceuticals, Inc. — Nationwide within the United States

  • Jul 18, 2022
    RECALLRecall (Class II): Irbesartan Tablets, USP, 150mg, 90- count bottles, Rx only, Manufactured by: Jubilant Generics Ltd. Roorkee- 247661, In…

    Failed dissolution specifications. — Recalling firm: Jubilant Cadista Pharmaceuticals, Inc. — Nationwide within the United States

  • Oct 12, 2021
    RECALLRecall (Class II): Irbesartan Tablets USP, 300 mg a) 30 count (NDC 68180-412-06) and b) 90 count NDC# 68180-412-09) bottles, Rx only

    CGMP Deviations: impurity N-nitrosoirbesartan detected in API — Recalling firm: Lupin Pharmaceuticals Inc. — Product was distributed to major distributors who may have further distributed the product nationwide.

  • Oct 12, 2021
    RECALLRecall (Class II): Irbesartan Tablets USP, 150 mg a) 30 count (NDC 68180-411-06) and b) 90 count (NDC 68180-411-09) bottles, Rx only

    CGMP Deviations: impurity N-nitrosoirbesartan detected in API — Recalling firm: Lupin Pharmaceuticals Inc. — Product was distributed to major distributors who may have further distributed the product nationwide.

  • Oct 12, 2021
    RECALLRecall (Class II): Irbesartan Tablets USP, 75 mg a) 30 count (NDC 68180-410-06) and b) 90 count (NDC 68180-410-09) bottles, Rx only

    CGMP Deviations: impurity N-nitrosoirbesartan detected in API — Recalling firm: Lupin Pharmaceuticals Inc. — Product was distributed to major distributors who may have further distributed the product nationwide.

  • Jan 18, 2019
    RECALLRecall (Class II): Irbesartan Tablets 300 mg 90 count Rx only Manufactured by: Zhejiang Huahai Pharmaceutical Co., Xunqiao, Linhai, Zh…

    CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million. — Recalling firm: Prinston Pharmaceutical Inc — Nationwide